Skip to main content
Clinical Trials/KCT0009198
KCT0009198
Recruiting
未知

Hativ electrocardiogram monitoring on Patients with Chemotherapy

Chonnam National University Hospital Hwasun Hospital0 sites300 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Chonnam National University Hospital Hwasun Hospital
Enrollment
300
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational Study
Sex
All

Investigators

Sponsor
Chonnam National University Hospital Hwasun Hospital

Eligibility Criteria

Inclusion Criteria

  • Adults aged 19 or older who own a smartphone.
  • Patients currently taking oral anticancer drugs for solid tumors, who have undergone an electrocardiogram within the past year as per the study enrollment criteria.
  • (Thyroid cancer/Breast cancer/Lung cancer: Abemaciclib, Alectinib, Capecitabine, Ceritinib, Crizotinib, Ibrutinib, Lapatinib, Lazertinib, Lenvatinib, Lorlatinib, Osimertinib, Ponatinib, Ribociclib, Sorafenib, Sunitinib, Vandetanib, Vemurafenib)

Exclusion Criteria

  • Individuals with physical disabilities preventing the use of the portable electrocardiogram device, hativ®.
  • Individuals with intracardiac devices such as pacemakers, ICD, CRT, VAD.
  • Subjects who are unable to read the informed consent form (illiterate, foreigners, etc.).
  • Patients deemed inappropriate for participation in the clinical study based on the judgment of the researchers

Outcomes

Primary Outcomes

Not specified

Similar Trials